Chemistry:XL-388
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H22FN3O4S |
| Molar mass | 455.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
XL-388 is a drug which acts as a potent and selective inhibitor of both subtypes of the mechanistic target of rapamycin (mTOR), mTORC1 and mTORC2.[1] It is being researched for the treatment of various forms of cancer,[2][3][4] and has also been used to demonstrate a potential application for mTOR inhibitors in the treatment of neuropathic pain.[5][6]
References
- ↑ "Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)". Journal of Medicinal Chemistry 56 (6): 2218–34. March 2013. doi:10.1021/jm3007933. PMID 23394126.
- ↑ "The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models". Oncotarget 7 (31): 49527–49538. August 2016. doi:10.18632/oncotarget.10389. PMID 27385099.
- ↑ "The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent". Oncotarget 8 (18): 30151–30161. May 2017. doi:10.18632/oncotarget.15620. PMID 28404914.
- ↑ "The therapeutic value of XL388 in human glioma cells". Aging 12 (22): 22550–22563. November 2020. doi:10.18632/aging.103791. PMID 33159013.
- ↑ "mTOR signaling intervention by Torin1 and XL388 in the insular cortex alleviates neuropathic pain". Neuroscience Letters 718: 134742. January 2020. doi:10.1016/j.neulet.2020.134742. PMID 31917234.
- ↑ "Manganese-enhanced MRI depicts a reduction in brain responses to nociception upon mTOR inhibition in chronic pain rats". Molecular Brain 13 (1): 158. November 2020. doi:10.1186/s13041-020-00687-1. PMID 33267907.
 |  |
